France to Ban HHC Synthetic Cannabis in Weeks

May.16.2023
France to Ban HHC Synthetic Cannabis in Weeks
France's Health Minister plans to ban HHC products, created from synthetic cannabis extract, within weeks due to regulatory loopholes.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not make recommendations on any products, nor does it provide commentary on any domestic policies pertaining to the industry.


The legality of the product mentioned in the article is limited to overseas only. Domestic readers are reminded to strictly abide by relevant laws and regulations in China.


This article does not provide any investment or consumption advice.


This article is not suitable for minors.


On May 15th, François Braun, the French Minister of Health, announced that products containing HHC (hexahydrocannabinol) may be banned in a few weeks.


When asked about issues related to hexahydrocannabinol (HHC) by the media, Braun told French radio station, "...


I believe that this (ban) will only be in effect for a few weeks.


According to reports, HHC is a molecule artificially synthesized from natural cannabis extract, and products based on HHC are currently not subject to sales or consumption restrictions in France.


In the past few months, health authorities in various countries, both in Europe and the United States, have noticed an increase in the sale of a certain substance through online or physical stores. Currently, not much is known about its effects, but addiction experts believe it has similar effects to tetrahydrocannabinol (THC), which is the primary psychoactive ingredient in cannabis.


Braun explained, "Currently, they are not classified as drugs. But I believe they will soon be.


Braun likened HHC to a regulatory loophole.


There is a loophole that needs to be quickly filled so that we no longer have such completely abnormal sales.


Reference:


The Health Minister announces that synthetic cannabis, HHC, will be banned within a few weeks.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Canada’s B.C. Passes First Vaping Cost-Recovery Framework, Allowing Government to Sue Manufacturers Over Health Expenses
Canada’s B.C. Passes First Vaping Cost-Recovery Framework, Allowing Government to Sue Manufacturers Over Health Expenses
According to the Nelson Star, British Columbia has passed the Vaping Product Damages and Health Care Costs Recovery Act by a 49–42 vote. The legislation enables the provincial government to seek recovery of future public health costs from vape manufacturers, following models used in opioid and tobacco litigation.
Dec.03
Scottish Retailers Urge Government to Fast-Track Nicotine Pouch Regulations
Scottish Retailers Urge Government to Fast-Track Nicotine Pouch Regulations
The Scottish Grocers’ Federation (SGF) is calling on the government to clarify the regulatory framework for nicotine pouches in order to prevent high-strength and illegal products from entering the market, stressing that these products should not be targeted at minors.
Dec.04 by 2FIRSTS.ai
JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up
JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up
Japan Tobacco (JT) delivered a strong Q3 2025. Revenue rose 18.3% year over year to ¥947.2 billion, with adjusted operating profit up 27.8% to ¥279.0 billion (+20.8% at constant currency) and net profit up 29.7% to ¥176.7 billion. Growth was led by reduced-risk products (RRP): total RRP volume climbed 40%, with heated tobacco (HTS) up 53%. In Japan, the launches of Ploom AURA and EVO pods pushed HTS category share to 15.5%, while the Ploom user base has nearly doubled versus two years ago.
Oct.30 by 2FIRSTS.ai
Belgian Drug Commissioner Warns of Hidden Opioids in Illegal Vapes
Belgian Drug Commissioner Warns of Hidden Opioids in Illegal Vapes
Belgium’s drug commissioner Ine Van Wymersch has warned that more than 80% of illegal refillable vape capsules seized in Belgium contain synthetic opioids, posing serious risks of early addiction among children. She told Euronews that these substances, which have no distinctive smell or color, could lead to opioid dependence from a young age.
Dec.08 by 2FIRSTS.ai
Heno Biotech Invited to Speak at PouchEX 2025 in Stockholm, Introduces Supply Chain Competency Model for the Nicotine Pouch Industry
Heno Biotech Invited to Speak at PouchEX 2025 in Stockholm, Introduces Supply Chain Competency Model for the Nicotine Pouch Industry
Heno Biotech was invited to deliver a keynote address at PouchEX Stockholm 2025, presenting a new supply chain competency model for the nicotine pouch sector. The company showcased its end-to-end capabilities—from scientific research and advanced manufacturing to global regulatory compliance—underscoring the critical role of supply chain upgrading in driving sustainable industry growth.
Nov.24
FDA CTP Acting Director  Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
FDA CTP Acting Director Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
At the FDLI Tobacco and Nicotine Policy Conference, FDA CTP Acting Director Bret Koplow spoke in favor of promoting tobacco harm reduction to reduce smoking. He backed a legal marketplace for authorized reduced-risk products, potential expansion of flavored e-cigs, and faster FDA reviews to ensure a strong, regulated market.
Oct.29 by 2FIRSTS.ai